IP Library Granted Patent US 10,213,407
Granted Patent B2
US 10,213,407 · App. 15/366,940 · Granted Feb 26, 2019

Compounds and methods for inhibiting production of trimethylamine

Inventors: Jose Carlos Garcia-Garcia (CIncinnati, OH); Stanley Leon Hazen (Pepper Pike, OH); John August Wos (Mason, OH)
Assignees: THE PROCTER & GAMBLE COMPANY; THE CLEVELAND CLINIC FOUNDATION
A61K31/26A61K31/04A61K31/095A61K31/145A61K31/166A61K31/216A61K31/22A61K31/27A61K31/275A61K31/325A61K31/336A61K31/351A61K31/439A61K31/4425A61K31/4453A61K31/452A61K31/5375A61K45/06C07C331/20C07D211/46C07D213/04C07D213/30C07D213/65C07D295/13C07D303/36C07D453/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,213,407
App. No.
15/366,940
Granted
Feb 26, 2019
Kind
B2
Abstract

The invention provides a method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) and lowering TMAO in an individual comprising administering to the individual a composition comprising a compound set forth in FORMULA (I): The invention also provides for a method of inhibiting the production of TMA by bacteria comprising administering to the individual a composition comprising a compound set forth in FORMULA (I) wherein the compound is administered in an amount effective to inhibit formation of trimethylamine (TMA) from choline or carnitine in the individual.

Claims (58)

1. A method of inhibiting the conversion of choline or carnitine to trimethylamine (TMA) by a bacterium comprising: contacting the bacterium with a compound as set forth in Formula (I):

wherein

Y + is selected from a quaternary nitrogen; X − is an anion; n is selected from 1, 2 or 3; R 2 and R 3 are independently selected from C1-4 alkyl or bound together forming an aliphatic, aromatic or heterocyclic ring system;

R 4 is selected from C1-4 alkyl, alkenyl, alkynyl, alkoxy carbonyl, alkoxy dicarbonyl, acrylic, alkoxy, alkoxy alkyl, aryloxy alkyl, alkyl carboxylate as part of a betaine, inner salt, or Zwitterion form, halo alkyl, hydroxy alkyl, nitrile, or propargyl;

R 6 is selected from C1-4 alkyl, alkoxy, hydroxy, alkoxy alkyl, hydroxy alkyl, or epoxy; and

including any acceptable salts or solvates thereof.

2. The method of claim 1 , wherein the compound is at least one of N-(2-Phenoxyethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate, N-(2-isothiocyanatoethyl)-N,N-dimethylprop-2-yn-1-aminium bromide, 3-Isothiocyanato-N,N-diethyl-N-methylpropanaminium iodide, and N-(2-isothiocyanatoethyl)-2-(methoxycarbonyl)-N,N-dimethylprop-2-en-1-aminium bromide, or pharmaceutically acceptable salts thereof.

3. The method of claim 1 , wherein the compound is at least one of N,N-Diethyl-2-isothiocyanato-N-methylpropanaminium iodide, N-(2-Bromoethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate, N-(Ethoxypropyl-2,3-dione)-3-isothiocyanato-N,N-diethylpropan-1-aminium bromide, or pharmaceutically acceptable salts thereof.

4. The method of claim 1 further comprising contacting the bacterium with a second agent that is at least one of Omega 3 oil, salicylic acid, dimethylbutanol, garlic oil, olive oil, krill oil, Co enzyme Q-10, a probiotic, a prebiotic, dietary fiber, psyllium husk, bismuth salts, phytosterols, grape seed oil, green tea extract, vitamin D, an antioxidant, turmeric, curcumin, resveratrol, activated charcoal, or copper chlorophyllin.

5. The method of claim 1 , wherein conversion of choline or carnitine to trimethylamine (TMA) is inhibited by from about 1% to about 100%.

6. The method of claim 1 , wherein conversion of choline or carnitine to trimethylamine (TMA) is inhibited by at least 50%.

7. The method of claim 1 , wherein the bacterium is at least one of Proteus mirabilis, Desulfovibrio alaskensis, Clostridium ljungdahlii, C. scindens, C. aldenense, C. aminobutyricum, Collinsella tanakaei, Anaerococcus vaginalis, Streptococcus dysgalactiae, Desultitobacterium hafniense, Klebsiella variicola, K pneumonia, Proteus penneri, Eggerthella lenta, Edwardsiella tarda, Escherichia coli , or E. fergusonii.

8. A method of inhibiting the conversion of choline to trimethylamine (TMA) by a bacterium comprising: contacting the bacterium with a compound set forth in Formula (II):

wherein R 1 is H, C 1 -C 4 alkoxy, Br, Cl, F, I, or is selected from

Y + is selected from a quaternary nitrogen; X − is an anion; n is selected from 1, 2 or 3; R 2 and R 3 are independently selected from C1-4 alkyl or bound together forming an aliphatic, aromatic or heterocyclic ring system;

Z is O, CH 2 , or H, H;

m is 0, 1 or 2;

R 5 is hydroxyl, or hydroxyl alkyl; and

R 7 is H, or C 1-4 alkyl; and

including any acceptable salts or solvates thereof.

9. The method of claim 8 , wherein the compound is at least one of N-(2-Phenoxyethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate, N-(2-isothiocyanatoethyl)-N,N-dimethylprop-2-yn-1-aminium bromide, 3-Isothiocyanato-N,N-diethyl-N-methylpropanaminium iodide, and N-(2-isothiocyanatoethyl)-2-(methoxycarbonyl)-N,N-dimethylprop-2-en-1-aminium bromide, or pharmaceutically acceptable salts thereof.

10. The method of claim 8 , wherein the compound is at least one of N,N-Diethyl-2-isothiocyanato-N-methylpropanaminium iodide, N-(2-Bromoethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate, N-(Ethoxypropyl-2,3-dione)-3-isothiocyanato-N,N-diethylpropan-1-aminium bromide, or pharmaceutically acceptable salts thereof.

11. The method of claim 8 further comprising contacting the bacterium with a second agent that is at least one of Omega 3 oil, salicylic acid, dimethylbutanol, garlic oil, olive oil, krill oil, Co enzyme Q-10, a probiotic, a prebiotic, dietary fiber, psyllium husk, bismuth salts, phytosterols, grape seed oil, green tea extract, vitamin D, an antioxidant, turmeric, curcumin, resveratrol, activated charcoal, or copper chlorophyllin.

12. The method of claim 8 , wherein conversion of choline or carnitine to trimethylamine (TMA) is inhibited by from about 1% to about 100%.

13. The method of claim 8 , wherein conversion of choline or carnitine to trimethylamine (TMA) is inhibited by at least 50%.

14. The method of claim 8 , wherein the bacterium is at least one of Proteus mirabilis, Desulfovibrio alaskensis, Clostridium ljungdahlii, C. scindens, C. aldenense, C. aminobutyricum, Collinsella tanakaei, Anaerococcus vaginalis, Streptococcus dysgalactiae, Desultitobacterium hafniense, Klebsiella variicola, K pneumonia, Proteus penneri, Eggerthella lenta, Edwardsiella tarda, Escherichia coli , or E. fergusonii.

15. A compound:

wherein R 1 is, C 1 -C 4 alkoxy, Br, Cl, F, I, or is selected from

Y + is selected from a quaternary nitrogen; X − is an anion; n is selected from 1, 2 or 3; R 2 and R 3 are independently selected from C1-4 alkyl or bound together forming an aliphatic, aromatic or heterocyclic ring system;

Z is O, CH 2 , or H, H;

m is 0, 1 or 2;

R 5 is hydroxyl, or hydroxyl alkyl; and

R 7 is H, or C 1-4 alkyl and

including any acceptable salts or solvates thereof.

16. The compound of claim 15 , wherein the compound is at least one compound selected from N-(Ethoxycarbonylethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium bromide; N-(Ethoxycarbonylethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium bromide; N-(Ethoxypropyl-2,3-dione)-2-isothiocyanato-N,N-dimethylethan-1-aminium bromide; N-(Ethoxypropyl-2,3-dione)-3-isothiocyanato-N,N-diethylpropan-1-aminium bromide; N-(2-Bromoethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-Cyanomethyl-2-isothiocyanato-N,N-diethylethan-1-aminium bromide; N-Cyanomethyl-3-isothiocyanato-N,N-diethylpropan-1-aminium bromide, N-(2-Phenoxyeth y)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(2-Benzyloxyethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(2-Benzyloxyethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(2-Phenoxyethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(2-Bromoethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(Oxiranylmethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(Oxiranylmethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(2-Methoxyethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(2-Methoxyethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(2-Ethoxyethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(2-Ethoxyethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(3-Methoxypropyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(3-Methoxyethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(2-Chloroethyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(3-Chloropropyl)-2-isothiocyanato-N,N-dimethylethan-1-aminium triflate; N-(2-Chloroethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(3-Chloropropyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; N-(2-Fluorooethyl)-3-isothiocyanato-N,N-diethylpropan-1-aminium triflate; 1-(2-Isothiocyanatoethyl)pyridin-1-ium bromide, 1-(2-Isothiocyanatoethyl)-3-hydroxypyridinium bromide, 1-(2-Isothiocyanatoethyl)-(2-hydroxymethyl)pyridinium triflate; 2-(hydroxymethyl)-1-(3-isothiocyanatopropyl)pyridin-1-ium trifluoromethanesulfonate; 3-hydroxy-1-(3-isothiocyanatopropyl)pyridin-1-ium trifluoromethanesulfonate; 1-(2-hydroxyethyl)-1-(2-isothiocyanatoethyl)piperidin-1-ium trifluoromethanesulfonate; 2-(hydroxymethyl)-1-(2-isothiocyanatoethyl)-1-methylpiperidin-1-ium trifluoromethanesulfonate: 1-(2-hydroxyethyl)-1-(3-isothiocyanatopropyl)piperidin-1-ium trifluoromethanesulfonate; N-(2-hydroxyethyl)-3-isothiocyanato-N,N-dimethylpropan-1-aminium trifluoromethanesulfonate; N-(2-isothiocyanatoethyl)-N,N-dimethylprop-2-yn-1-aminium bromide; N-(2-isothiocyanatoethyl)-2-(methoxycarbonyl)-N,N-dimethylprop-2-en-1-aminium bromide; 4-hydroxy-1-(2-isothiocyanatoethyl)-1-methylpiperidin-1-ium bromide; 4-Methyl-4-(2-isothiocyanatoethyl)morpholinium trifluoromethanesulfonate; 1-Methyl-1-(2-isothiocyanatoethyl)piperidium trifluoromethanesulfonate; 1-(2-Isothiocyanatoethyl)quinuclidinium trifluoromethanesulfonate; 4-Methyl-4-(3-isothiocyanatopropyl)morpholinium trifluoromethanesulfonate; or 1-Methyl-1-(3-isothiocyanatopropyl)piperidinium trifluoromethanesulfonate; 1-(3-Isothiocyanatopropyl)quinuclidinium trifluoromethanesulfonate.

17. A method of preparing a compound as set forth in FORMULA (II) comprising:

wherein R 1 is C 1 -C 4 alkoxy, Br, Cl, F, I, or is selected from

Y + is selected from a quaternary nitrogen; X − is an anion; n is selected from 1, 2 or 3; R 2 and R 3 are independently selected from C1-4 alkyl or bound together forming an aliphatic, aromatic or heterocyclic ring system;

Z is O, CH 2 , or H, H;

m is 0, 1 or 2;

R 5 is hydroxyl, or hydroxyl alkyl; and

R 7 is H, or C1-4 alkyl; and

including any acceptable salts or solvates thereof;

reacting compound A;

with a compound of structure B:

wherein LG is a suitable leaving group known to one skilled in the art.

18. A method of preparing a compound as set forth in FORMULA (II) comprising:

wherein R 1 is H, C 1 -C 4 alkoxy, Br, Cl, F, I, or is selected from

Y + is selected from a quaternary nitrogen; X − is an anion; n is selected from 1, 2 or 3; R 2 and R 3 are independently selected from C1-4 alkyl or bound together forming an aliphatic, aromatic or heterocyclic ring system;

Z is O, CH 2 , or H, H;

m is 0, 1 or 2;

R 5 is hydroxyl, or hydroxyl alkyl; and

R 7 is H, or C1-4 alkyl; and

including any acceptable salts or solvates thereof;

reacting compound C:

With a compound of structure D:

wherein LG is a suitable leaving group known to one skilled in the art.

19. Method of claim 18 wherein the leaving group LG is at least one of chloride, bromide, iodide, triflate, mesylate, or tosylate.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2019
From: GARCIA-GARCIA, JOSE CARLOS; WOS, JOHN AUGUST
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 047925/0163 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 8, 2019
From: HAZEN, STANLEY LEON
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 047925/0169 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2019
From: GARCIA-GARCIA, JOSE CARLOS (NMN); WOS, JOHN AUGUST
To: THE PROCTER & GAMBLE COMPANY
Reel/Frame 047920/0569 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 7, 2019
From: HAZEN, STANLEY LEON
To: THE CLEVELAND CLINIC FOUNDATION
Reel/Frame 047920/0726 →
Continuity (4)
Provisional Application 62261645 · Dec 1, 2015
Provisional Application 62261662 · Dec 1, 2015
Provisional Application 62356422 · Jun 29, 2016
Related Publication 20170152222A1 · Jun 1, 2017